Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'
Tweet Send to a Friend
BMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $328.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
